Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection
The Journal of Infectious Diseases · 14.08.2025 · 232 (2) · 465-473
DOI: 10.1093/infdis/jiaf105 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 01.03.2025. Verfasst von Xinyi Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: F.I. Proctor Foundation, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Herpes Zoster, Cardiovascular Diseases, Herpes Zoster Vaccine, Antiviral Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, Office of Research on Women's Health, National Institutes of Health.
Abstract (Originalsprache)
Background
Herpes zoster (HZ) is associated with a higher risk of cardiovascular events, but the effect of the recombinant zoster vaccine (RZV) on this risk, alone or in combination with antiviral treatment, remains uncertain. The aim of this study was to evaluate the impact of RZV on the risk of cardiovascular disease (CVD) events following HZ infection.
Methods
We conducted a retrospective cohort study using the Optum Labs Data Warehouse. Adults aged ≥50 years with HZ diagnosed between 1 January 2018 and 31 March 2023 were included. Participants were categorized by their receipt of RZV and antiviral treatment for HZ. A Cox multivariable proportional hazards model estimated the association with post-HZ cardiovascular events.
Results
Among 112 637 patients with HZ, 5240 (4.7%) received both RZV and antiviral therapy, 2644 (2.3%) received RZV alone, 80 871 (71.8%) received antiviral therapy alone, and 23 882 (21.2%) received neither. RZV alone reduced the CVD risk by 21% (95% confidence interval, 6%–33%), antiviral therapy alone by 22% (16%–26%), and receipt of both by 39% (28%–47%).
Conclusions
This study underscores the effectiveness of RZV and antiviral therapy in mitigating cardiovascular risks after HZ infection. Having both preventive vaccination and therapeutic antiviral intervention may offer enhanced protection against CVD and death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- F.I. Proctor Foundation, University of California, San Francisco, California, USA.
- Department of Ophthalmology, University of California, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
ORCID-Profile: Emily Tang, Benjamin F Arnold
Förderung
- NEI NIH HHS
- Office of Research on Women's Health
- National Institutes of Health
- National Eye Institute
- Department of Ophthalmology
- University of California
- Research to Prevent Blindness
Zitieren
APA
Xu, X., Ray, I., Tang, E., Arnold, B. F., & Acharya, N. R. (2025). Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection. The Journal of Infectious Diseases, 232(2), 465-473. https://doi.org/10.1093/infdis/jiaf105
Vancouver
Xu X, Ray I, Tang E, Arnold BF, Acharya NR. Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection. The Journal of Infectious Diseases. 2025;232(2):465-473. doi:10.1093/infdis/jiaf105
BibTeX
@article{Xu2025,
author = {Xu, Xinyi and Ray, Isabel and Tang, Emily and Arnold, Benjamin F and Acharya, Nisha R},
title = {Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {232},
number = {2},
pages = {465--473},
doi = {10.1093/infdis/jiaf105}
}
EUVIMED